Iovance Biotherapeutics Inc (IOVA)

$3.69 -0.18 (-4.65%)
Market Cap 1.52B
Revenue (ttm) 263.50M
Net Income (ttm) -390.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.38%
Debt to Equity Ratio 0.00
Volume 23,502,000
Avg Vol 16,063,918
Day's Range N/A - N/A
Shares Out 411.96M
Stochastic %K 4%
Beta 0.69
Analysts Strong Sell
Price Target $8.36

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
kangaroojaack
kangaroojaack Mar. 22 at 4:46 AM
$IOVA I made so much money off this it’s almost unspeakable
0 · Reply
DigitalOperationsNetwork
DigitalOperationsNetwork Mar. 22 at 4:45 AM
$IOVA biotech, just watching calmly.
0 · Reply
Trigga_tha_Gambler
Trigga_tha_Gambler Mar. 22 at 3:22 AM
$IOVA Lol. Lambo longs are riding this penny stock into a bear market.
0 · Reply
dogbone98
dogbone98 Mar. 22 at 2:16 AM
$IOVA Looks like Gastman will be speaking about 5001 on Thursday at 10AM at SITC. His fellow panelists includes Stephanie Goff from the NCI who's on TIL pioneer Rosenberg's team. I notice a few presentations at SITC from BMS as well as one by J&J, so a few BP's in attendance. Woud be nice to get some good news/data next week, get us back in the 4's.
1 · Reply
drose0527
drose0527 Mar. 21 at 11:27 PM
$IOVA I have a question for long IOVA holders. Why do you think buyout is on table and where do you put that valuation at I’m very curious cause my valuation based on where currently IOVA is with pipe line and now having a legitimate candidate for cancer tells me that this stock is in current re-valuation mode here on it’s current path. Please let me know what your valuation would be on buy out ?? I haven’t been here more than 6-8 weeks but I need to put my own collective puzzle together. To me I think IOVA is very much poised to run things alone without a buy out.
4 · Reply
TheBigShart81
TheBigShart81 Mar. 21 at 9:53 PM
$IOVA Not IOVA related but, it was 18 degrees here when I left the house Monday morning. Its 93 here, now. Insane.
3 · Reply
PJB1013
PJB1013 Mar. 21 at 8:39 PM
$IOVA very
0 · Reply
polloboy
polloboy Mar. 21 at 4:44 PM
$IOVA thanks again for your technical analysis, it’s real fascinating! I believe currently the stock price is more influenced by the macro environment and thus has been flowing in the direction of the overall market and will continue to do so in the near term based on the direction of this war and the impact it has. I guess we will see this week. I did buy 10,000 shares late Friday at $3.68 as a new starter position.
1 · Reply
drose0527
drose0527 Mar. 21 at 4:24 PM
$IOVA as we prep for wave 3 launch impulse 1. The average move to the upside IOVA has been running is 13 days. If it were to repeat the same exact movement from launch of last wave 1 impulse 1 is would be 8 days. So that gives us a window or 8-13 days. Where we will be back at 5.64. But with each wave extension. Wave 3 and impulse 3 usually is the fastest and most time compressed. Which means price moves quicker than time does. So my expectation would be impulse 1 would run closer to the lower end of average by 1-2 days. We could get to 5.64 in roughly 5.5 days. Where we will test liquidity there for 1-2 days. This is not the final move impulse 1 makes I think impulse 1 will move closer to 6.08 before we begin to experience a real heavy capitulation. There I would believe would be the closer to the 13th day which would bring impulse 1 to an end. Thus create impulse 2 sell off. Back to 5.64 could go to 5.15 in the most structured allowed retrace. Volume on Monday has to be there!
3 · Reply
BioCrazy1
BioCrazy1 Mar. 21 at 3:20 PM
$IOVA No real options volume till June and thats even on the light side. Bring them catalysts!
1 · Reply
Latest News on IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Mar 20, 2026, 5:15 PM EDT - 1 day ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 11, 2026, 12:42 PM EDT - 10 days ago

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

What's Going On With Iovance Biotherapeutics Stock On Friday?

Mar 6, 2026, 1:06 PM EST - 15 days ago

What's Going On With Iovance Biotherapeutics Stock On Friday?

Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years

Mar 4, 2026, 12:17 PM EST - 17 days ago

Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years

Iovance Biotherapeutics to Present at Upcoming Conferences

Feb 26, 2026, 8:00 AM EST - 23 days ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)

Feb 24, 2026, 3:43 PM EST - 25 days ago

Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Feb 24, 2026, 2:14 PM EST - 25 days ago

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 12:57 PM EST - 25 days ago

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Feb 24, 2026, 7:00 AM EST - 25 days ago

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Feb 24, 2026, 7:00 AM EST - 25 days ago

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Feb 11, 2026, 4:05 PM EST - 5 weeks ago

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Feb 5, 2026, 5:15 PM EST - 6 weeks ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Iovance Biotherapeutics: Bright Prospects For 2026

Dec 29, 2025, 12:51 AM EST - 2 months ago

Iovance Biotherapeutics: Bright Prospects For 2026

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode

Nov 11, 2025, 1:24 PM EST - 4 months ago

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode

Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:16 PM EST - 4 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Oct 29, 2025, 8:15 AM EDT - 5 months ago

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play

Oct 10, 2025, 10:30 AM EDT - 5 months ago

Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Aug 21, 2025, 4:56 PM EDT - 7 months ago

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 18, 2025, 4:15 PM EDT - 7 months ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:15 AM EDT - 8 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Aug 7, 2025, 4:01 PM EDT - 8 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 23, 2025, 12:08 PM EDT - 8 months ago

Here's why Iova stock surged 32% today and why the rally might not be over

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Jul 18, 2025, 12:02 PM EDT - 8 months ago

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 15, 2025, 7:30 AM EDT - 8 months ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 9:04 AM EDT - 8 months ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 14, 2025, 7:30 AM EDT - 8 months ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 11, 2025, 10:32 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 9 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 10, 2025, 8:18 AM EDT - 9 months ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 3, 2025, 7:35 AM EDT - 9 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

Jul 2, 2025, 5:46 PM EDT - 9 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 28, 2025, 7:46 AM EDT - 9 months ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Jun 26, 2025, 4:45 PM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

Jun 26, 2025, 9:00 AM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jun 24, 2025, 12:03 PM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 20, 2025, 9:07 AM EDT - 9 months ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

Jun 18, 2025, 2:34 PM EDT - 9 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 18, 2025, 8:38 AM EDT - 9 months ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 9 months ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

kangaroojaack
kangaroojaack Mar. 22 at 4:46 AM
$IOVA I made so much money off this it’s almost unspeakable
0 · Reply
DigitalOperationsNetwork
DigitalOperationsNetwork Mar. 22 at 4:45 AM
$IOVA biotech, just watching calmly.
0 · Reply
Trigga_tha_Gambler
Trigga_tha_Gambler Mar. 22 at 3:22 AM
$IOVA Lol. Lambo longs are riding this penny stock into a bear market.
0 · Reply
dogbone98
dogbone98 Mar. 22 at 2:16 AM
$IOVA Looks like Gastman will be speaking about 5001 on Thursday at 10AM at SITC. His fellow panelists includes Stephanie Goff from the NCI who's on TIL pioneer Rosenberg's team. I notice a few presentations at SITC from BMS as well as one by J&J, so a few BP's in attendance. Woud be nice to get some good news/data next week, get us back in the 4's.
1 · Reply
drose0527
drose0527 Mar. 21 at 11:27 PM
$IOVA I have a question for long IOVA holders. Why do you think buyout is on table and where do you put that valuation at I’m very curious cause my valuation based on where currently IOVA is with pipe line and now having a legitimate candidate for cancer tells me that this stock is in current re-valuation mode here on it’s current path. Please let me know what your valuation would be on buy out ?? I haven’t been here more than 6-8 weeks but I need to put my own collective puzzle together. To me I think IOVA is very much poised to run things alone without a buy out.
4 · Reply
TheBigShart81
TheBigShart81 Mar. 21 at 9:53 PM
$IOVA Not IOVA related but, it was 18 degrees here when I left the house Monday morning. Its 93 here, now. Insane.
3 · Reply
PJB1013
PJB1013 Mar. 21 at 8:39 PM
$IOVA very
0 · Reply
polloboy
polloboy Mar. 21 at 4:44 PM
$IOVA thanks again for your technical analysis, it’s real fascinating! I believe currently the stock price is more influenced by the macro environment and thus has been flowing in the direction of the overall market and will continue to do so in the near term based on the direction of this war and the impact it has. I guess we will see this week. I did buy 10,000 shares late Friday at $3.68 as a new starter position.
1 · Reply
drose0527
drose0527 Mar. 21 at 4:24 PM
$IOVA as we prep for wave 3 launch impulse 1. The average move to the upside IOVA has been running is 13 days. If it were to repeat the same exact movement from launch of last wave 1 impulse 1 is would be 8 days. So that gives us a window or 8-13 days. Where we will be back at 5.64. But with each wave extension. Wave 3 and impulse 3 usually is the fastest and most time compressed. Which means price moves quicker than time does. So my expectation would be impulse 1 would run closer to the lower end of average by 1-2 days. We could get to 5.64 in roughly 5.5 days. Where we will test liquidity there for 1-2 days. This is not the final move impulse 1 makes I think impulse 1 will move closer to 6.08 before we begin to experience a real heavy capitulation. There I would believe would be the closer to the 13th day which would bring impulse 1 to an end. Thus create impulse 2 sell off. Back to 5.64 could go to 5.15 in the most structured allowed retrace. Volume on Monday has to be there!
3 · Reply
BioCrazy1
BioCrazy1 Mar. 21 at 3:20 PM
$IOVA No real options volume till June and thats even on the light side. Bring them catalysts!
1 · Reply
AirForce7
AirForce7 Mar. 21 at 1:32 PM
$IOVA https://x.com/IManghaila/status/2035185378857021631?s=20
1 · Reply
Passthehotsauce
Passthehotsauce Mar. 21 at 1:00 PM
$IOVA After a couple hours of research, this is the chart ChatGPT put together based of the info I attained. Even the “Bear Case” is showing a 19% return. That’s how undervalued she is right now. I just got here, and will open a position next week, but does anyone who’s been here longer see a problem these numbers or any of the info? From where I’m sitting, this set up is about as good as you could ask for. Ultra Bullish IMO.
5 · Reply
Alibayli
Alibayli Mar. 21 at 8:43 AM
$IOVA Friends, let me ask a question so we can discuss and exchange ideas on this topic: To what extent is the tension between the U.S. and Europe due to the war negatively impacting approval in the United Kingdom?
5 · Reply
SlaveLifeAllLife
SlaveLifeAllLife Mar. 21 at 7:29 AM
$IOVA Sold covered calls, now i have FOMO : D Hopefully it stays below $5 for another month.
1 · Reply
MikeyDread
MikeyDread Mar. 21 at 7:14 AM
$IOVA play along wall st games.. get paid
1 · Reply
kangaroojaack
kangaroojaack Mar. 21 at 6:45 AM
$IOVA they have the magic sauce with Amtagvi now incorporate Ai streamline manufacturing and administration. Fire all non essential employees, yes more layoffs anyone not clinical or sales or compliance/fda facing.
1 · Reply
BioCrazy1
BioCrazy1 Mar. 21 at 6:42 AM
$IOVA I hadn't seen this interview before. Its informative. I like this stuff because you can get a glimpse into the treatment first hand from Dr's using it. https://m.youtube.com/watch?v=VeWfs2n1GcI&pp=iggCQAE%3D&fbclid=IwVERDUAQrHOFleHRuA2FlbQIxMABzcnRjBmFwcF9pZAwzNTA2ODU1MzE3MjgAAR5N3TRX9yCBs0YWgcqUZ4jiuzRIf4f3UHIU0bnAU1sHMk0EdBeDlQDXCdAY9g_aem_Sjep5KT6bTCeHYnnmShp_g
0 · Reply
BioCrazy1
BioCrazy1 Mar. 21 at 5:13 AM
$IOVA https://www.stockinsights.ai/us/IOVA/8-K/management-changes-20260320-ea0?utm_source=twitter&utm_medium=social&utm_id=secfilingsdigest
1 · Reply
kaoz
kaoz Mar. 21 at 3:12 AM
$IOVA The donut chart confirms it: 74.74% of all order flow is large-scale buying ($31.78M inflow vs just $5M outflow). This isn’t retail noise — it’s big players with research access positioning ahead of more upside.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Mar. 21 at 2:49 AM
$IOVA
1 · Reply
EvrytIsNothingWithaTwist
EvrytIsNothingWithaTwist Mar. 21 at 1:19 AM
$IOVA thanks kaoz for sharing: bullish as hell signal… big institutions are aggressively buying, positioning ahead of possibly something BIG: expected news / guidance FDA-related catalyst…
2 · Reply
EvrytIsNothingWithaTwist
EvrytIsNothingWithaTwist Mar. 21 at 1:10 AM
$IOVA almost 4-week guidance delay after earnings is NOT normal… possible reasons: 1. something material is pending with the U.S. Food and Drug Administration; 2. they don’t have clean numbers yet, so giving guidance could backfire; 3. strategic silence possibly signaling something behind the scenes (partnership or buyout discussions, they expect a major update soon); 4. manufacturing / capacity constraints; … in the meantime stock stays weak because uncertainty = discount… whatever it is, they know it, we don’t🤔
5 · Reply